ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026

Core Viewpoint - ADMA Biologics, Inc. will participate in the J.P. Morgan Healthcare Conference on January 12, 2026, highlighting its focus on specialty biologics for immunodeficient patients [1]. Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company that manufactures, markets, and develops specialty biologics aimed at treating immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™ for primary humoral immunodeficiency, BIVIGAM for primary immunodeficiency, and NABI-HB for enhanced immunity against hepatitis B [3]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia [3]. - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, which collects source plasma for its products [3]. - ADMA holds numerous U.S. and foreign patents related to its products and candidates [3].